Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFα monoclonal antibody and by pentoxiphylline

Lupus

Volumn 10, Issue 1, 2001, Pages 23-31

  Segal, R ^a   Dayan, M ^a   Zinger, H ^a   Mozes, E ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Anti TNF; Experimental SLE

Indexed keywords

CYTOKINE; DNA ANTIBODY; INTERLEUKIN 1; MONOCLONAL ANTIBODY; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; IMMUNOASSAY; IMMUNOHISTOLOGY; LUPUS ERYTHEMATOSUS; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 0035002214     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120301675275538     Document Type: Article

References (39)

1. Induction of a systemic lupus erythematosus-like disease by a common human anti-DNA idiotype
2. Kinetics of cytokine production in experimental systemic lupus erythematosus: Involvement of T helper cell 1/T helper cell 2-type cytokines in disease
3. Methotrexate treatment in murine experimental SLE; clinical benefits associated with cytokine manipulation
4. The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations
5. The beneficial effect of the estrogen antagonist tamoxifen on experimental SLE
6. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus
7. Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα srIL-2α levels and disease activity in systemic lupus erythematosus
8. Renal expression of IL-6 and TNF α genes in lupus nephritis
9. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity
10. TNF α and IL-1 sequentially induce endothelial ICAM-1 and VCAM-1 expression in MRL/lpr lupus-prone mice
11. 1 lupus-prone mice
12. Expansion and high proliferative potential of the macrophage system throughout life time of lupus-prone NZB/W and MRL-lpr/lpr mice. Lack of down-regulation of extramedullar macrophage proliferation in the postnatal period
13. Spontaneous production of tumor necrosis factor alpha by Kupffer cells of MRL/lpr mice
14. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis
15. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene region
16. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis
17. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of the TNF-α
18. Inhibitions of endogenous TNF formation by pentoxifylline
19. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway
20. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees
21. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats
22. Pentoxifylline. A review of its pharmacodynamic and pharmacokentic properties and its therapeutic effects
23. Phosphodiesterase inhibitor pentoxifylline: An antiinflammatory immunomodulator drug potentially useful in some rheumatic diseases
24. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis
25. Pentoxifylline in the treatment of children with new-onset type I diabetes mellitus
26. Pentoxifylline, a phoshodiesterase inhibitor induces immune deviation in patients with multiple sclerosis
27. Efficacy of pentoxifylline in the treatment of refractory nephrotic syndrome in lupus nephritis
28. In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice
29. Tumor necrosis factor and other cytokines in murine lupus
30. Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms
31. Tumor necrosis factor and IL-1 in New Zealand black/white mice. Enhanced gene expression and acceleration of renal injury
32. TNF-α enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease
33. Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/W F1 mice
34. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus
35. Novel and enhanced IL-1 gene expression in autoimmune mice with lupus
36. Differential cytokine expression in acute and chronic murine graft-versus-host disease
37. The role of cytokines in the immunopathogenesis of lupus
38. The cytokine network in the pathogenesis of SLE and possible therapeutic implications
39. Interleukin 1 enhances the development of spontaneous arthritis in MRL/lpr mice